TYK2 Pipeline Watch: Oral ESK-001 Improves Psoriasis in Phase 2 OLE Study
ESK-001, an investigational oral tyrosine kinase 2 (TYK2) inhibitor, shows promise in psoriasis, according to 28-week data from the open-label extension (OLE) period of the Phase 2 STRIDE clinical trial. In the study, ESK-001 was generally well tolerated, and most patients treated with the top dose of 40mg twice daily achieved Psoriasis Area and Severity […]